Dana G. Mead Jr.
Dana G. Mead Jr.'s purchase track record
Dana G. Mead Jr. has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/11/2026 | MOBI | $105K | +6.1% | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Mobia Medical Announces Q3 2026 Earnings Release Date. Mobia Medical Inc. has set November 5, 2026 as the date to release its third‑quarter 2026 financial results. The announcement comes as the company prepares to share its latest performance data. Investors will be able to see how the company’s operations and revenue compare to expectations. The disclosure follows the company’s recent trading near its 52‑week range.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays Starts Coverage of Inspire Medical with Underweight. Barclays has begun coverage of Inspire Medical Systems and assigned an Underweight rating. The firm set a price target of $65 for the stock. This rating follows the recent analyst activity on the company. The stock is currently near its long‑term support level.
Transaction History
| LUNG | ▲ Buy | Grant | 40,000 | $0 | 6/5/2026 | View on chart |
| MOBI | ▲ Buy | Open Market | 7,000 | $105K | 5/11/2026 | View on chart |
| INSP | ▲ Buy | Grant | 3,562 | $0 | 4/30/2026 | View on chart |
| LUNG | ▲ Buy | Grant | 37,153 | $0 | 6/2/2025 | View on chart |
| INSP | ▲ Buy | Grant | 1,266 | $0 | 5/1/2025 | View on chart |
| LUNG | ▲ Buy | Grant | 15,216 | $0 | 6/3/2024 | View on chart |
| INSP | ▲ Buy | Grant | 716 | $0 | 5/2/2024 | View on chart |
| LUNG | ▲ Buy | Grant | 12,620 | $0 | 6/1/2023 | View on chart |
| INSP | ▲ Buy | Grant | 669 | $0 | 4/27/2023 | View on chart |
| LUNG | ▲ Buy | Grant | 5,600 | $0 | 6/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Pulmonx Sets Q3 2026 Earnings Date for October 27
Pulmonx Corporation has announced that it will report its third-quarter 2026 financial results on October 27, 2026. This scheduled update provides a specific timeline for investors to review the company's latest performance metrics. The announcement serves as a standard corporate disclosure rather than a change in business operations.
Pulmonx Sets Q3 2026 Earnings Date for October 27. Pulmonx Corporation has announced that it will report its third-quarter 2026 financial results on October 27, 2026. This scheduled update provides a specific timeline for investors to review the company's latest performance metrics. The announcement serves as a standard corporate disclosure rather than a change in business operations.